An announcement from ANGLE plc ( (GB:AGL) ) is now available.
ANGLE plc, in collaboration with BioView, has presented new analytical validation data for its HER2-CTC assay at the AACR Annual Meeting in Chicago. The data highlights the high sensitivity and specificity of the assay, which is designed to assess HER2 status in circulating tumor cells from blood samples. This minimally invasive method can identify changes in HER2 status over time, potentially offering new treatment options for patients with metastatic breast cancer whose HER2 status may have evolved. This advancement underscores ANGLE’s commitment to providing innovative solutions that could improve patient outcomes by enabling dynamic monitoring of cancer biomarkers.
More about ANGLE plc
ANGLE plc is a world-leading liquid biopsy company specializing in circulating tumor cell (CTC) solutions for research, drug development, and clinical oncology. The company’s FDA-cleared Parsortix® PC1 System enables comprehensive downstream analysis of blood samples, including whole cell imaging and molecular analysis. ANGLE focuses on clinical services and diagnostic products, with its services offered through GCLP-compliant laboratories.
YTD Price Performance: -12.20%
Average Trading Volume: 1,476,722
Technical Sentiment Signal: Buy
Current Market Cap: £29.03M
See more insights into AGL stock on TipRanks’ Stock Analysis page.